ITCI US46116X1019

Report

Delayed Nasdaq - 04:00:01 2023-02-06 pm EST
47.52	USD		-2.86%

01/13	RBC Cuts Price Target on Intra-Cellular Therapies to $72 From $74, Maintains Outperform Rating	MT
01/09	Intra-cellular Therapies, Inc. : Entry into a Material Definitive Agreement (form 8-K)	AQ
01/09	Transcript : Intra-Cellular Therapies, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-09-2023 11:15 AM	CI

News

Analyst Reco.

Official Publications

Sector news

Analyst Recommendations on INTRA-CELLULAR THERAPIES, INC.

01/13	RBC Cuts Price Target on Intra-Cellular Therapies to $72 From $74, Maintains Outperform..	MT
2022	RBC Lifts Price Target on Intra-Cellular Therapies to $69 From $67, Maintains Outperfor..	MT
2022	RBC Cuts Price Target on Intra-Cellular Therapies to $67 From $70, Maintains Outperform..	MT
2022	Analyst recommendations: Snowflake, Vipshop, UIta Beauty, VF, Ad..
2022	Goldman Sachs Cuts Intra-Cellular Therapies to Neutral From Buy, Price Target to $49 Fr..	MT
2022	Mizuho Securities Adjusts Intra-Cellular Therapies' Price Target to $72 From $75, Keeps..	MT
2022	Needham Adjusts Intra-Cellular Therapies' Price Target to $67 from $65, Keeps Buy Ratin..	MT
2022	Goldman Sachs Lowers Intra-Cellular Therapies' Price Target to $64 From $71, Maintains ..	MT
2022	Mizuho Securities Initiates Intra-Cellular Therapies at Buy with $75 Price Target	MT
2022	RBC Lifts Price Target on Intra-Cellular Therapies to $71 From $70, Maintains Outperfor..	MT
2022	Mizuho Initiates Intra-Cellular Therapies With Buy Rating, $75 Price Target, Cites 'Add..	MT
2022	UBS Initiates Coverage on Intra-Cellular Therapies With Buy Rating, $75 Price Target	MT
2022	Piper Sandler Starts Intra-Cellular Therapies at Neutral With $59 Price Target	MT
2022	SVB Leerink Adjusts Intra-Cellular Therapies Price Target to $70 From $65, Maintains Ou..	MT
2022	RBC Capital Adjusts Intra-Cellular Therapies' Price Target to $70 From $65, Maintains O..	MT
2022	SVB Leerink Adjusts Intra-Cellular Therapies' Price Target to $65 from $50, Keeps Outpe..	MT
2022	RBC Raises Price Target on Intra-Cellular Therapies to $65 From $55, Maintains Outperfo..	MT
2022	Needham Lifts Intra-Cellular Therapies Price Target to $65 From $59, Maintains Buy Rati..	MT
2022	Goldman Sachs Starts Intra-Cellular Therapies at Buy With $64 Price Target	MT
2021	RBC Boosts Price Target on Intra-Cellular Therapies to $55 From $50 as FDA Approves Cap..	MT
2021	Jefferies Adjusts Price Target for Intra-Cellular Therapies to $85 From $70, Maintains ..	MT
2021	Canaccord Genuity Adjusts Intra-Cellular Therapies PT to $88 From $81	MT
2021	Needham Adjusts Price Target on Intra-Cellular Therapies to $59 From $55, Maintains Buy..	MT
2021	SVB Leerink Adjusts Intra-Cellular Therapies' Price Target to $50 from $45, Keeps Outpe..	MT
2021	RBC Lifts Price Target on Intra-Cellular Therapies to $50 From $48, Maintains Outperfor..	MT
2021	Intra Cellular Therapies : RBC Raises Price Target on Intra-Cel..	MT
2021	Intra Cellular Therapies : RBC Trims Price Target on Intra-Cell..	MT
2021	Intra Cellular Therapies : Needham Starts Intra-Cellular Therap..	MT
2021	Intra Cellular Therapies : Jefferies Adjusts Intra-Cellular The..	MT
2021	Intra Cellular Therapies : RBC Capital Adjusts Intra-Cellular T..	MT
2021	Intra Cellular Therapies : RBC Boosts Price Target on Intra-Cel..	MT
2021	Intra Cellular Therapies : RBC Capital Adjusts Price Target on ..	MT
2021	Intra Cellular Therapies : RBC Capital Adjusts Price Target on ..	MT
2020	Intra Cellular Therapies : Cantor Fitzgerald Adjusts Price Targ..	MT
2020	Intra Cellular Therapies : Goldman Sachs Starts Intra-Cellular ..	MT
2020	Intra Cellular Therapies : BTIG Adjusts Intra-Cellular Therapie..	MT
2020	Intra Cellular Therapies : RBC Capital Adjusts Intra-Cellular T..	MT

Upcoming event on INTRA-CELLULAR THERAPIES, INC.

03/01/23

FY 2022 Earnings Release (Projected)

Company calendar

Upcoming sector events

02/07/23	VERTEX PHARMACEUTICALS INCORPORATED : FY 2022 Earnings Release
03/21/23	WUXI APPTEC CO., LTD. : FY 2022 Earnings Release
03/29/23	BIONTECH SE : FY 2022 Earnings Release (Projected)
04/26/23	BEIGENE, LTD. : FY 2022 Earnings Release

More events

Sector

Healthcare
	Pharmaceuticals & Medical Research
		Biotechnology & Medical Research
			Biotechnology & Medical Research
				Bio Therapeutic Drugs